Department of Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
ANZ J Surg. 2022 Dec;92(12):3232-3236. doi: 10.1111/ans.17992. Epub 2022 Aug 25.
Although patients with ulcerative colitis (UC) are at increased risk of rectal cancer compared to the general population, it remains unclear whether their oncologic outcomes are different than sporadic rectal cancer (S-RC).We aimed to compare survival and oncologic outcomes in S-RC versus UC-associated rectal cancer (UC-RC).
We performed a retrospective case-control study of patients who underwent surgical resection for rectal cancer between 2005 and 2015. Data collected included patient demographics, intraoperative variables, postoperative outcomes, and oncological outcomes.
A total of 138 patients were included; 92 patients with S-RC and 46 with UC-RC. Both groups were comparable in terms of demographics, oncologic characteristics, oncologic treatment strategies, perioperative complications and operative factors except for preoperative radiotherapy. At a median follow-up time of 3.7 years the 3-and 5-year OS rates; the 1-and 3-year DFS rates were comparable between the groups.
Ulcerative colitis-associated rectal cancer patients have similar survival and oncologic outcomes as sporadic rectal cancer patients.
与普通人群相比，溃疡性结肠炎（UC）患者罹患直肠癌的风险增加，但UC 相关直肠癌（UC-RC）患者的肿瘤学结局是否与散发性直肠癌（S-RC）不同尚不清楚。本研究旨在比较 S-RC 与 UC-RC 患者的生存和肿瘤学结局。
我们对 2005 年至 2015 年间接受直肠癌手术切除的患者进行了回顾性病例对照研究。收集的数据包括患者的人口统计学资料、术中变量、术后结局和肿瘤学结局。
共纳入 138 例患者，其中 92 例为 S-RC，46 例为 UC-RC。两组在人口统计学特征、肿瘤学特征、肿瘤学治疗策略、围手术期并发症和手术因素方面无差异，除术前放疗外。在中位随访 3.7 年后，两组患者的 3 年和 5 年 OS 率以及 1 年和 3 年的 DFS 率无差异。
UC 相关直肠癌患者的生存和肿瘤学结局与散发性直肠癌患者相似。
